0000899243-22-028856.txt : 20220816 0000899243-22-028856.hdr.sgml : 20220816 20220816185441 ACCESSION NUMBER: 0000899243-22-028856 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220812 FILED AS OF DATE: 20220816 DATE AS OF CHANGE: 20220816 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Stuckley Carol CENTRAL INDEX KEY: 0001863298 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35945 FILM NUMBER: 221171636 MAIL ADDRESS: STREET 1: C/O CENTESSA PHARMACEUTICALS PLC STREET 2: D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3FH ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Epizyme, Inc. CENTRAL INDEX KEY: 0001571498 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261349956 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-229-5872 MAIL ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-12 1 0001571498 Epizyme, Inc. EPZM 0001863298 Stuckley Carol C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR CAMBRIDGE MA 02139 1 0 0 0 Common Stock, par value $0.0001 2022-08-12 4 D 0 25696 D 0 D Reflects disposition of restricted stock units ("RSUs") in accordance with that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. ("Merger Sub"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding shares of the Issuer, at a price per Share of (i) $1.45 per Share (the "Cash Consideration"), plus (ii) one (1) contractual contingent value right per Share ("CVR"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any, and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on August 12, 2022. (Continued from Footnote 1) Pursuant to the Merger Agreement, effective immediately prior to the effective time of the Merger, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each share underlying such RSU, in each case, less applicable withholding. /s/ John Weidenbruch, attorney-in-fact 2022-08-16